Denmark· DK-28105374614
Xydalba
A dalbavancin product containing dalbavancinhydrochlorid, registered in Denmark by Allergan Pharmaceuticals Int.Ltd. The same ATC class is registered in 16 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Dalbavancin is registered in 16 of 19 countries.
Countries holding a registration under ATC J01XA04 (dalbavancin), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Dalbavancin · ATC J01XA04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Dalbavancinhydrochlorid
- Manufacturer
- Allergan Pharmaceuticals Int.Ltd
- Country
- Denmark (DK)
- ATC code
- J01XA04
- ATC class
- Dalbavancin
- Defined daily dose
- 1.5 g, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105374614
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
7 interactions on record for dalbavancin.
Graded by severity as the source publishes them — 7 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dalbavancin · interactions on record
7 records
- 7 moderate
Most severe, free to view
- Sodium picosulfateA06AB08moderate
- Levonorgestrel and ethinylestradiolG03AA07moderate
- Desogestrel and ethinylestradiolG03AA09moderate
- Drospirenone and ethinylestradiolG03AA12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01XA04
Dalbavancin, as other registers publish it.
- United StatesDalbavancinSomerset Therapeutics, LLC
- United StatesDalbavancinBE Pharmaceuticals Inc.
- United StatesDalbavancinTeva Pharmaceuticals, Inc.
- United StatesDalbavancinMeitheal Pharmaceuticals Inc
- United StatesDalbavancinLong Grove Pharmaceuticals, LLC
- DenmarkDalbavancin "Adalvo"AdAlvo Limited
- DenmarkDalbavancin "Baxter"Baxter Holding B.V.
- DenmarkDalbavancin "Teva"Teva B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fef6ec6a-6ec5-45a1-b449-6a606f75356d GET /v1/drugs/fef6ec6a-6ec5-45a1-b449-6a606f75356d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "pulver til koncentrat til infusionsvæske",
"source": "dkma",
"strength": "500 mg",
"auth_role": "MOD",
"dk_drugid": "28105374614",
"substance": "Dalbavancinhydrochlorid",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "42054"
}See everything about dalbavancin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.